High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

Breast Cancer Research and Treatment

Volumn 153, Issue 2, 2015, Pages 383-389

  Callens, Céline ^a   Debled, Marc ^b   Delord, Marc ^c   Turbiez Stalain, Isabelle ^a   Veyret, Corinne ^b   Bièche, Ivan ^a   Brain, Etienne ^a  

^a INSTITUT CURIE   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Breast cancer; Docetaxel; Febrile neutropenia; Pharmacogenetics; SLCO1A2

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE PLUS DOXORUBICIN; DNA; DOCETAXEL; DOCETAXEL PLUS DOXORUBICIN; DOXORUBICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; THYMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ORGANIC ANION TRANSPORTER; SLCO1A2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; DRUG TRANSPORT; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE DOSAGE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HAPLOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1A2 GENE; ALLELE; BREAST NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; COMPLICATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEBRILE NEUTROPENIA; FEMALE; HAPLOTYPES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84940946972     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3552-7     Document Type: Article

References (35)

1. Brain EG, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard JC, Extra JM, Combe M, Fourme E, Nogues C et al (2005) Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 293(19):2367–2371
2. Woodward EJ, Twelves C (2010) Scheduling of taxanes: a review. Curr Clin Pharmacol 5(3):226–231
3. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229–239
4. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99(5):967–972
5. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266
6. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296–1302
7. Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C, Beijnen JH (1996) Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24(6):655–658
8. Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, Ferlini A (2010) Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 124(2):593–598
9. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6(7):2598–2603
10. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102(5):1016–1023
11. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski L (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279(37):38379–38385
12. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274(10):6043–6046
13. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276(18):14581–14587
14. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4(8):815–818
15. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116(5):824–829
16. Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJ, Tan EH, Lim WT, Chowbay B (2011) The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 67(6):1471–1478
17. Chew SC, Lim J, Singh O, Chen X, Tan EH, Lee EJ, Chowbay B (2013) Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients, Eur J Clin Pharmacol
18. Hor SY, Lee SC, Wong CI, Lim YW, Lim RC, Wang LZ, Fan L, Guo JY, Lee HS, Goh BC et al (2008) PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 8(2):139–146
19. Tham LS, Holford NH, Hor SY, Tan T, Wang L, Lim RC, Lee HS, Lee SC, Goh BC (2007) Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res 13(23):7126–7132
20. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genom 23(1):29–33
21. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79(6):570–580
22. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J et al (2011) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70(2):425–434
24. Benjamini YHY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57(1):12
25. Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78(3):260–277
26. Zhou F, Zheng J, Zhu L, Jodal A, Cui PH, Wong M, Gurney H, Church WB, Murray M (2013) Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2. AAPS J 15(4):1099–1108
27. Gong IY, Kim RB (2013) Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28(1):4–18
28. von Minckwitz G (2007) Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother 8(4):485–495
29. Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ et al (2013) Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 31(34):4283–4289
30. von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C et al (2008) Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292–298
31. Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of Four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6(3):133–140
32. Jenkins P, Scaife J, Freeman S (2012) Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 23(7):1766–1771
33. Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K, Tomlinson I, Kerr D (2014) ‘Toxgnostics’: an unmet need in cancer medicine. Nat Rev Cancer 14(6):440–445
34. Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J (2012) Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 13(16):1979–1988
35. Brain EG, Debled M, Eymard JC, Bachelot T, Extra JM, Serin D, Combe M, Fourme E: Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients. Abstract #4101, 31st Annual San Antonio Breast Cancer Cancer Symposium. Breast Cancer Res Treat December 10–14, 2008, 107 (suppl 1)